Novel Strategies in the Development of New Therapies, Drug Substances and Drug Carriers
This book is conceived to promote synergy between research and industrial activities in the design and development of new drugs and, therefore, is not limited to any specific aspect of development. It covers the entire process from the identification of a molecular target, studies of drug–protein in...
Saved in:
| HerausgeberIn: | |
|---|---|
| Sonstige: | |
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 electronic resource (450 p.) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 06464nam-a2201885z--4500 | ||
|---|---|---|---|
| 001 | 993553548704498 | ||
| 005 | 20231214132846.0 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 202208s2022 xx |||||o ||| 0|eng d | ||
| 035 | |a (CKB)5600000000483093 | ||
| 035 | |a (oapen)https://directory.doabooks.org/handle/20.500.12854/91173 | ||
| 035 | |a (EXLCZ)995600000000483093 | ||
| 041 | 0 | |a eng | |
| 100 | 1 | |a Kutner, Andrzej |4 edt | |
| 245 | 1 | 0 | |a Novel Strategies in the Development of New Therapies, Drug Substances and Drug Carriers |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 electronic resource (450 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 520 | |a This book is conceived to promote synergy between research and industrial activities in the design and development of new drugs and, therefore, is not limited to any specific aspect of development. It covers the entire process from the identification of a molecular target, studies of drug–protein interactions, the modeling and optimization of the functional activity, design and chemical synthesis, biological evaluation, and the development of new pharmaceutical carriers.The original articles and reviews are focused on the design and development of new anticancer treatments, new anticancer low-molecular-weight agents as potential drug substances, and the elucidation of their mechanisms of action. The book also includes studies on novel modulators of the serotonergic system used to treat central nervous system disorders, novel agents against infectious diseases, and the development of anti-plasmodial and anti-inflammatory agents. The successful identification of new compounds for development as drug substances comes from rich sources of medicinal plants and medicinal chemistry approaches. | ||
| 546 | |a English | ||
| 650 | 7 | |a Research & information: general |2 bicssc | |
| 650 | 7 | |a Chemistry |2 bicssc | |
| 653 | |a alpha-ketoglutarate | ||
| 653 | |a cell cycle | ||
| 653 | |a apoptosis | ||
| 653 | |a JNK | ||
| 653 | |a cell migration | ||
| 653 | |a cell invasion | ||
| 653 | |a TGF-β | ||
| 653 | |a VEGF | ||
| 653 | |a glycoconjugates | ||
| 653 | |a methotrexate | ||
| 653 | |a cancer treatment | ||
| 653 | |a glucose metabolism | ||
| 653 | |a drug design and discovery | ||
| 653 | |a anticancer drugs | ||
| 653 | |a targeted therapy | ||
| 653 | |a Warburg effect | ||
| 653 | |a antidepressants | ||
| 653 | |a pyrido[1,2-c]pyrimidines | ||
| 653 | |a dual 5-HT1A/SERT activity | ||
| 653 | |a drug design | ||
| 653 | |a anticancer activity | ||
| 653 | |a lung cancer | ||
| 653 | |a resveratrol | ||
| 653 | |a PRI-2191 | ||
| 653 | |a vitamin D | ||
| 653 | |a active substance delivery systems | ||
| 653 | |a biomedical hydrogels | ||
| 653 | |a active substance-controlled release | ||
| 653 | |a genistein | ||
| 653 | |a hydrogels for cosmetology | ||
| 653 | |a hydrogels for dermatology | ||
| 653 | |a transdermal active substance delivery systems | ||
| 653 | |a histone deacetylase (HDAC) | ||
| 653 | |a depression | ||
| 653 | |a biomarker | ||
| 653 | |a anti-depressant therapy | ||
| 653 | |a human DNA topoisomerase | ||
| 653 | |a cancer | ||
| 653 | |a drug | ||
| 653 | |a molecular docking | ||
| 653 | |a synthesis | ||
| 653 | |a fluorine | ||
| 653 | |a vitamin D3 | ||
| 653 | |a metabolite | ||
| 653 | |a A-ring | ||
| 653 | |a CD-ring | ||
| 653 | |a side-chain | ||
| 653 | |a nanoparticles | ||
| 653 | |a molecular modeling | ||
| 653 | |a oxidation mechanisms | ||
| 653 | |a electrochemistry | ||
| 653 | |a MALDI | ||
| 653 | |a spectroscopic data | ||
| 653 | |a cytotoxic study | ||
| 653 | |a self-assembled monolayer | ||
| 653 | |a gold electrode | ||
| 653 | |a multimodal activity | ||
| 653 | |a calcium-sensing receptor | ||
| 653 | |a enantiomer | ||
| 653 | |a calcimimetic | ||
| 653 | |a calcilytic | ||
| 653 | |a colon cancer | ||
| 653 | |a stereospecificity | ||
| 653 | |a HT-29 | ||
| 653 | |a IL-8 | ||
| 653 | |a inflammation | ||
| 653 | |a cyclooxygenase | ||
| 653 | |a 1,2,4-triazole | ||
| 653 | |a pyridazinone | ||
| 653 | |a SAR | ||
| 653 | |a anti-inflammatory activity | ||
| 653 | |a antioxidant activity | ||
| 653 | |a ADME | ||
| 653 | |a anticancer drug | ||
| 653 | |a antimicrobial peptide (AMP) | ||
| 653 | |a dermaseptin | ||
| 653 | |a frog skin peptides | ||
| 653 | |a LHRH | ||
| 653 | |a prostate cancer | ||
| 653 | |a Phyllomedusa bicolor | ||
| 653 | |a therapeutic peptides | ||
| 653 | |a copper (II) complexes | ||
| 653 | |a thiourea | ||
| 653 | |a cytotoxic activity | ||
| 653 | |a proteome analysis | ||
| 653 | |a antimicrobial activity | ||
| 653 | |a major latex protein | ||
| 653 | |a Chelidonium majus | ||
| 653 | |a greater celandine | ||
| 653 | |a defense-related proteins | ||
| 653 | |a alkaloids | ||
| 653 | |a cancer cells | ||
| 653 | |a vitamin D receptor | ||
| 653 | |a split luciferase-based biosensor | ||
| 653 | |a CYP24A1-dependent metabolism | ||
| 653 | |a CYP27B1 | ||
| 653 | |a rickets | ||
| 653 | |a genome editing | ||
| 653 | |a vitamin D biology and action | ||
| 653 | |a transcription | ||
| 653 | |a ChIP-chip analysis | ||
| 653 | |a distal enhancers | ||
| 653 | |a histone H3 acetylation | ||
| 653 | |a RNA polymerase II | ||
| 653 | |a analogue actions at genes | ||
| 653 | |a vitamin D hormone (1,25(OH)2D3) | ||
| 653 | |a latex | ||
| 653 | |a antiviral proteins | ||
| 653 | |a antimicrobial compounds | ||
| 653 | |a cytotoxicity | ||
| 653 | |a drug discovery | ||
| 653 | |a CRISPR/Cas9 | ||
| 653 | |a tetrahydro-β-carbolines | ||
| 653 | |a Plasmodium falciparum (P. falciparum) | ||
| 653 | |a antimalarial | ||
| 653 | |a antiparasitic agents | ||
| 653 | |a hemolysis | ||
| 653 | |a vitamin D analogs | ||
| 653 | |a 25 vitamin D 24-hydroxylase | ||
| 653 | |a CYP24A1 | ||
| 653 | |a proliferation | ||
| 653 | |a high-grade serous ovarian cancer cells | ||
| 653 | |a gold | ||
| 653 | |a Au(III) complex | ||
| 653 | |a colorectal cancer | ||
| 653 | |a organometallic | ||
| 653 | |a cancer therapy | ||
| 653 | |a metallodrugs | ||
| 776 | |z 3-0365-4646-4 | ||
| 776 | |z 3-0365-4645-6 | ||
| 700 | 1 | |a Brown, Geoffrey |4 edt | |
| 700 | 1 | |a Kallay, Enikö |4 edt | |
| 700 | 1 | |a Kutner, Andrzej |4 oth | |
| 700 | 1 | |a Brown, Geoffrey |4 oth | |
| 700 | 1 | |a Kallay, Enikö |4 oth | |
| 906 | |a BOOK | ||
| ADM | |b 2023-12-15 05:34:20 Europe/Vienna |f system |c marc21 |a 2022-08-13 21:17:26 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5339474420004498&Force_direct=true |Z 5339474420004498 |b Available |8 5339474420004498 | ||